More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.30B
EPS
-1.21
P/E ratio
--
Price to sales
3238.71
Dividend yield
--
Beta
1.65195
Previous close
$46.36
Today's open
$46.16
Day's range
$43.14 - $46.41
52 week range
$12.56 - $58.94
show more
CEO
Paul A. LaViolette
Employees
116
Headquarters
Hayward, CA
Exchange
NASDAQ Capital Market
Shares outstanding
73548924
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
What Pulse Biosciences (PLSE) Said on Its Q3 Earnings Call
Pulse Biosciences NASDAQ: PLSE said it completed enrollment ahead of schedule in the pivotal U.S. study of its nPulse Cardiac Catheter, setting up a data readout expected in the third quarter of 2027 as the company increases spending on clinical development and launch preparations.
MarketBeat • Nov 6, 2026

Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced interim six-month results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic and hyperfunctioning benign thyroid nodules (BTNs). The results were presented at the 95th Annual Meet.
Business Wire • Nov 6, 2026

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the third quarter ended September 30, 2026. “Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan,” said.
Business Wire • Nov 5, 2026

Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Misses Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.29 per share a year ago.
Zacks Investment Research • Nov 6, 2026

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Stifel 2026 Healthcare Conference in New York, NY. Pulse Biosciences' Management is scheduled to present on Thursday, November 12, at 11:20 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and P.
Business Wire • Oct 29, 2026

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in l.
Business Wire • Oct 22, 2026

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to.
Business Wire • Oct 14, 2026

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were appr.
Business Wire • Oct 9, 2026

Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York. A presentation at the Symposium will feature preclinical applications of two nPulse prototype endoc.
Business Wire • Oct 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Pulse Biosciences Inc commission-free¹. Build wealth for the long term using automated trading and transfers.